Cargando…
Nucleic Acid Drugs for Prevention of Cardiac Rejection
Heart transplantation has been broadly performed in humans. However, occurrence of acute and chronic rejection has not yet been resolved. Several inflammatory factors, such as cytokines and adhesion molecules, enhance the rejection. The graft arterial disease (GAD), which is a type of chronic reject...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804055/ https://www.ncbi.nlm.nih.gov/pubmed/20069118 http://dx.doi.org/10.1155/2009/916514 |
_version_ | 1782176131987800064 |
---|---|
author | Suzuki, Jun-ichi Isobe, Mitsuaki Morishita, Ryuichi Nagai, Ryozo |
author_facet | Suzuki, Jun-ichi Isobe, Mitsuaki Morishita, Ryuichi Nagai, Ryozo |
author_sort | Suzuki, Jun-ichi |
collection | PubMed |
description | Heart transplantation has been broadly performed in humans. However, occurrence of acute and chronic rejection has not yet been resolved. Several inflammatory factors, such as cytokines and adhesion molecules, enhance the rejection. The graft arterial disease (GAD), which is a type of chronic rejection, is characterized by intimal thickening comprised of proliferative smooth muscle cells. Specific treatments that target the attenuation of acute rejection and GAD formation have not been well studied in cardiac transplantation. Recent progress in the nucleic acid drugs, such as antisense oligodeoxynucleotides (ODNs) to regulate the transcription of disease-related genes, has important roles in therapeutic applications. Transfection of cis-element double-stranded DNA, named as “decoy,” has been also reported to be a useful nucleic acid drug. This decoy strategy has been not only a useful method for the experimental studies of gene regulation but also a novel clinical strategy. In this paper, we reviewed the experimental results of NF-κB, E2F, AP-1, and STAT-1 decoy and other ODNs using the experimental heart transplant models. |
format | Text |
id | pubmed-2804055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28040552010-01-12 Nucleic Acid Drugs for Prevention of Cardiac Rejection Suzuki, Jun-ichi Isobe, Mitsuaki Morishita, Ryuichi Nagai, Ryozo J Biomed Biotechnol Review Article Heart transplantation has been broadly performed in humans. However, occurrence of acute and chronic rejection has not yet been resolved. Several inflammatory factors, such as cytokines and adhesion molecules, enhance the rejection. The graft arterial disease (GAD), which is a type of chronic rejection, is characterized by intimal thickening comprised of proliferative smooth muscle cells. Specific treatments that target the attenuation of acute rejection and GAD formation have not been well studied in cardiac transplantation. Recent progress in the nucleic acid drugs, such as antisense oligodeoxynucleotides (ODNs) to regulate the transcription of disease-related genes, has important roles in therapeutic applications. Transfection of cis-element double-stranded DNA, named as “decoy,” has been also reported to be a useful nucleic acid drug. This decoy strategy has been not only a useful method for the experimental studies of gene regulation but also a novel clinical strategy. In this paper, we reviewed the experimental results of NF-κB, E2F, AP-1, and STAT-1 decoy and other ODNs using the experimental heart transplant models. Hindawi Publishing Corporation 2009 2009-12-31 /pmc/articles/PMC2804055/ /pubmed/20069118 http://dx.doi.org/10.1155/2009/916514 Text en Copyright © 2009 Jun-ichi Suzuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Suzuki, Jun-ichi Isobe, Mitsuaki Morishita, Ryuichi Nagai, Ryozo Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title | Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title_full | Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title_fullStr | Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title_full_unstemmed | Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title_short | Nucleic Acid Drugs for Prevention of Cardiac Rejection |
title_sort | nucleic acid drugs for prevention of cardiac rejection |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804055/ https://www.ncbi.nlm.nih.gov/pubmed/20069118 http://dx.doi.org/10.1155/2009/916514 |
work_keys_str_mv | AT suzukijunichi nucleicaciddrugsforpreventionofcardiacrejection AT isobemitsuaki nucleicaciddrugsforpreventionofcardiacrejection AT morishitaryuichi nucleicaciddrugsforpreventionofcardiacrejection AT nagairyozo nucleicaciddrugsforpreventionofcardiacrejection |